Domů › Trojně negativní rakovina prsu › Kalifornie › Los Angeles
Klinické studie Trojně negativní rakovina prsu v Los Angeles, CA
27 studií pro Trojně negativní rakovina prsu hledá účastníky v lokalitách v Los Angeles a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Probíhá náborFáze 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Probíhá náborFáze 1
- University of California - Los Angeles, Los Angeles
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Probíhá náborFáze 3
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Probíhá náborFáze 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Probíhá náborFáze 2
- Ellison Institute of Technology (EITM), Los Angeles
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Probíhá náborFáze 3
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Probíhá náborFáze 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Probíhá náborFáze 2/3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Probíhá náborFáze 1/2
- Cedars-Sinai Medical Center, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Probíhá náborFáze 1/2
- University of California Los Angeles Medical Center, Los Angeles
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Probíhá náborFáze 1
- University of California LA, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Probíhá náborFáze 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
Probíhá náborFáze 1
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Probíhá náborFáze 1
- Start Lacn, Los Angeles
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Probíhá náborFáze 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Probíhá náborFáze 2
- University of Southern California, Los Angeles
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Probíhá náborFáze 2
- Cedars-Sinai Medical Center, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
Probíhá náborVítáni zdraví dobrovolníci
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Probíhá náborFáze 1/2
- Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Probíhá náborFáze 1/2
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Probíhá náborFáze 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Probíhá náborFáze 1
- University of Southern California, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Probíhá náborFáze 2
- Valkyrie Clinical Trials, Los Angeles
Studie Trojně negativní rakovina prsu v jiných městech
- Houston, TX42 studií
- New York City, NY31 studií
- Nashville, TN28 studií
- Boston, MA26 studií
- San Antonio, TX23 studií
- St. Louis, MO21 studií
- Arlington, VA20 studií
- Atlanta, GA20 studií
- Dallas, TX18 studií
- Chicago, IL16 studií
- Columbus, OH16 studií
- Grand Rapids, MI15 studií
Další studie v Los Angeles
- Nemalobuněčný plicní karcinom87 studií
- Rakovina (všechny typy)74 studií
- Rakovina prsu73 studií
- Rakovina prostaty61 studií
- Kolorektální karcinom59 studií
- Metastatický karcinom57 studií
- Rakovina vaječníků50 studií
- Rakovina plic45 studií
- Squamózní buněčný karcinom hlavy a krku42 studií
- Rakovina slinivky břišní35 studií
- Rakovina endometria34 studií
- Melanom34 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.